ATyr Net Tangible Assets vs Long Term Debt Total Analysis
| LIFE Stock | USD 1.73 0.03 1.70% |
ATyr Pharma financial indicator trend analysis is way more than just evaluating aTyr Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether aTyr Pharma is a good investment. Please check the relationship between ATyr Pharma Net Tangible Assets and its Long Term Debt Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.
Net Tangible Assets vs Long Term Debt Total
Net Tangible Assets vs Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of aTyr Pharma Net Tangible Assets account and Long Term Debt Total. At this time, the significance of the direction appears to have pay attention.
The correlation between ATyr Pharma's Net Tangible Assets and Long Term Debt Total is -1.0. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of aTyr Pharma, assuming nothing else is changed. The correlation between historical values of ATyr Pharma's Net Tangible Assets and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of aTyr Pharma are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Net Tangible Assets i.e., ATyr Pharma's Net Tangible Assets and Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | -1.0 |
| Relationship Direction | Negative |
| Relationship Strength | Strong |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Long Term Debt Total
Most indicators from ATyr Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into aTyr Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 38.61, whereas Selling General Administrative is forecasted to decline to about 12.3 M.
| 2023 | 2024 (projected) | Total Operating Expenses | 52.5M | 49.9M | Non Recurring | 65.5M | 64.8M |
ATyr Pharma fundamental ratios Correlations
Click cells to compare fundamentals
ATyr Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ATyr Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 36.2M | 38.7M | 115.5M | 95.8M | 122.1M | 116.0M | |
| Other Current Liab | 2.4M | 3.6M | 4.0M | 9.9M | 23.1M | 40.5M | |
| Total Current Liabilities | 12.9M | 5.9M | 6.0M | 13.9M | 16.4M | 15.6M | |
| Total Stockholder Equity | 21.0M | 31.5M | 109.1M | 71.3M | 90.7M | 86.1M | |
| Net Tangible Assets | 21.2M | 31.7M | 109.1M | 71.5M | 82.2M | 86.3M | |
| Retained Earnings | (322.3M) | (338.5M) | (372.3M) | (417.6M) | (468.0M) | (444.6M) | |
| Accounts Payable | 847K | 1.4M | 1.0M | 3.1M | 3.5M | 3.4M | |
| Cash | 9.2M | 17.0M | 2.3M | 10.0M | 22.5M | 21.4M | |
| Non Current Assets Total | 4.3M | 3.0M | 1.8M | 14.7M | 19.1M | 18.1M | |
| Non Currrent Assets Other | 172K | 213K | 158K | (22K) | 131K | 124.5K | |
| Cash And Short Term Investments | 31.1M | 31.7M | 107.9M | 69.3M | 98.2M | 156.6M | |
| Common Stock Total Equity | 30K | 31K | 4K | 11K | 9.9K | 9.4K | |
| Short Term Investments | 21.9M | 14.7M | 105.6M | 56.2M | 75.6M | 42.2M | |
| Liabilities And Stockholders Equity | 36.2M | 38.7M | 115.5M | 95.8M | 122.1M | 116.0M | |
| Non Current Liabilities Total | 2.2M | 1.4M | 398K | 10.6M | 15.2M | 14.4M | |
| Other Current Assets | 781K | 2.0M | 5.4M | 3.0M | 2.4M | 2.3M | |
| Other Stockholder Equity | 343.4M | 370.0M | 481.7M | 489.3M | 558.7M | 289.5M | |
| Total Liab | 15.2M | 7.2M | 6.4M | 24.5M | 31.6M | 30.0M | |
| Total Current Assets | 31.9M | 35.7M | 113.7M | 81.1M | 103.0M | 97.8M | |
| Short Term Debt | 9.5M | 861K | 980K | 894K | 1.3M | 1.3M | |
| Common Stock | 4K | 11K | 28K | 29K | 63K | 59.9K | |
| Property Plant Equipment | 4.1M | 3.0M | 1.8M | 11.6M | 10.4M | 9.9M | |
| Other Assets | 172K | 1K | 158K | 3.4M | 1.0 | 0.95 | |
| Accumulated Other Comprehensive Income | (40K) | (43K) | (263K) | (433K) | (74K) | (70.3K) | |
| Short Long Term Debt Total | 3.0M | 2.2M | 1.4M | 11.5M | 15.1M | 10.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether aTyr Pharma is a strong investment it is important to analyze ATyr Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ATyr Pharma's future performance. For an informed investment choice regarding ATyr Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.Note that the aTyr Pharma information on this page should be used as a complementary analysis to other ATyr Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for ATyr Stock analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is ATyr Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATyr Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.88) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.29) | Return On Equity (0.56) |
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATyr Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATyr Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATyr Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.